Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 14,635 Cr.
- Current Price ₹ 704
- High / Low ₹ 802 / 650
- Stock P/E 154
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 11.5 %
- ROE 9.90 %
- Face Value ₹ 1.00
Pros
- Debtor days have improved from 85.6 to 66.6 days.
- Company's working capital requirements have reduced from 192 days to 140 days
Cons
- Company has a low return on equity of 4.53% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 695 | 725 | 751 | 841 | 1,157 | 1,419 | |
| 520 | 556 | 587 | 716 | 990 | 1,131 | |
| Operating Profit | 175 | 170 | 164 | 125 | 167 | 288 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% |
| 6 | 18 | 27 | 28 | 27 | 29 | |
| Interest | 24 | 21 | 32 | 51 | 74 | 81 |
| Depreciation | 44 | 52 | 72 | 80 | 88 | 107 |
| Profit before tax | 112 | 114 | 88 | 22 | 33 | 129 |
| Tax % | 35% | 30% | 25% | 30% | 26% | 26% |
| 73 | 80 | 65 | 16 | 24 | 95 | |
| EPS in Rs | ||||||
| Dividend Payout % | 0% | 0% | 0% | 444% | 279% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 24% |
| TTM: | 23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 13% |
| TTM: | 287% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 5% |
| Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 18 | 18 | 18 | 18 |
| Reserves | 700 | 778 | 850 | 873 | 895 | 993 |
| 250 | 304 | 637 | 752 | 870 | 868 | |
| 246 | 291 | 312 | 464 | 349 | 361 | |
| Total Liabilities | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 |
| 373 | 617 | 659 | 701 | 923 | 1,074 | |
| CWIP | 116 | 79 | 236 | 345 | 151 | 107 |
| Investments | 0 | 22 | 63 | 64 | 80 | 80 |
| 722 | 671 | 858 | 996 | 977 | 979 | |
| Total Assets | 1,212 | 1,389 | 1,816 | 2,106 | 2,131 | 2,240 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 127 | 109 | -26 | 88 | 221 | 251 | |
| -158 | -259 | -279 | -95 | -111 | -190 | |
| 268 | -1 | 304 | 81 | -190 | -85 | |
| Net Cash Flow | 237 | -152 | -2 | 75 | -80 | -24 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 98 | 103 | 87 | 67 |
| Inventory Days | 86 | 77 | 124 | 185 | 123 | 73 |
| Days Payable | 208 | 247 | 244 | 284 | 176 | 161 |
| Cash Conversion Cycle | 0 | -34 | -21 | 4 | 35 | -22 |
| Working Capital Days | 133 | 144 | 250 | 246 | 190 | 140 |
| ROCE % | 13% | 9% | 4% | 6% | 11% |
Documents
Announcements
Annual reports
No data available.
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.